# A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

> **NCT06302491** · PHASE2 · RECRUITING · sponsor: **Kind Pharmaceuticals LLC** · enrollment: 64 (estimated)

## Conditions studied

- β -Thalassemia

## Interventions

- **DRUG:** AND017 capsules
- **DRUG:** AND017 Placebo

## Key facts

- **NCT ID:** NCT06302491
- **Lead sponsor:** Kind Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06302491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06302491, "A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06302491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*